Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of oral LUM-201 versus active comparator in prepubertal children with idiopathic growth hormone deficiency
MOH_2021-08-25_010204Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibutamoren in growth hormone deficiency (GHD) and idiopathic growth hormone deficiency (I-GHD) (4 arms), sponsored by Lumos Pharma, Inc. Primary endpoint: Safety and tolerability of daily oral LUM-201. Started Jul 2021; status: completed.
02
Drugs
ibutamoren
03
Conditions
growth hormone deficiency (GHD)idiopathic growth hormone deficiency (I-GHD)
Beyond the preview
Go deeper on MOH_2021-08-25_010204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-25_010204.